Sernova Corp T.SVA

Melton off to Vertex

[BioTeck]

https://www.biospace.com/article/harvard-researcher-heads-to-vertex-to-curate-diabetes-portfolio/

[Metalsguy1]

interesting read. Between the utter lack of progress at Sernova and more than a year of looking for patient 7 like the holy grail on one hand and these kind of high profile moves, could we ask for more of a flashing neon exit sign? I have been holding out for a buyout, now I will settle for being able to make a timely exit before the whole market realizes what a sham SVA is. If only they worked to

[BioTeck]

They should sell themselves to Vertex at this point. Vertex has the cells, we have a device. They pay us 3 bucks a share and we all move on. Lets get on it Spillup, I'm fine with 3 bucks at this point because i know you won't be able to get us the true value anyway. 

[Mercuryfilling1]

Bringing in an expensive pinch hitter doesn't guarantee you a world series title. Melton will be just as constrained as Witkowski by all the protocols, safety concerns, finding patients etc. This will be a slow crawl (whether partnered or separately) to the finish line, not a mad dash. Vertex published "positive" 90 day data for their 1st patient in October last year. The results